Company
United StatesPublic company, NASDAQ: EXELExelixis, Inc. (NASDAQ: EXEL), Alameda, CA – FDA Inspections
Inspection records and compliance data for Exelixis, Inc. in Alameda, California. 3 FDA inspections on record (1 OAI), 1 Form 483, last inspected May 05, 2026. Publicly traded as NASDAQ: EXEL.
Company Profile
This profile covers Exelixis, Inc. based in Alameda, California, United States.
FDA Inspection History
- FDA inspections
- 3
- OAI
- 1
- VAI
- 0
- NAI
- 1
- Unclassified
- 1
- Form 483s
- 1
- Warning letters
- 0
First inspected September 27, 2012. Last inspected May 5, 2026.
Most cited issue areas
- General responsibilities of sponsors2 inspections
- Investigator non-compliance1 inspection
FDA inspections (3)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| May 5, 2026 | Not classified | Human Drugs · Bioresearch Monitoring | 1319178 |
| March 27, 2018 | NAI | Human Drugs · Bioresearch Monitoring | 1049904 |
| September 27, 2012 | OAI | Human Drugs · Bioresearch Monitoring | 802660 |
FDA documents
EIRs (1)
People (2)
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Exelixis, Inc.
Stock ticker
EXEL
Exchange
NASDAQ
Share price
$69.84
Market cap
$17.0B
Price as of
November 13, 2026
FEI Number
3006375488
Address
1851 Harbor Bay Pkwy, Alameda, California 94502, United States
Country
United States
ID: 9bd9218c-af48-40bb-a20d-bd3e4fb4f674